Avalo Therapeutics Q1'26 Revenue Estimate at $0, EPS Expected at ($1.18) Ahead of April 30 Release
AVTX has more than doubled off its 52-week low of $3.39.
Summary
Avalo Therapeutics is expected to report Q1'26 revenue of $0 and an EPS loss of ($1.18) when it announces results on April 30. This estimate provides a baseline for investor expectations, indicating the company is not anticipated to generate significant product revenue in the near term. The company's last 10-K for 2025 reported a widened net loss and increased cash burn, making these Q1 estimates consistent with a clinical-stage biotech. Traders will be watching the actual results against these estimates, as well as any updates on its pipeline development and cash runway, especially given the existing $750M universal shelf registration.
At the time of this announcement, AVTX was trading at $14.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $330.4M. The 52-week trading range was $3.39 to $20.72. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.